FDA Inspection 1271780 — LEK Pharmaceuticals d.d.

LEK Pharmaceuticals d.d. — FEI 3002807463

The FDA completed an inspection of LEK Pharmaceuticals d.d. on November 24, 2022 in Lendava. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
November 24, 2022
Fiscal Year
2023
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Lendava (Slovenia)

Additional Details

Mutual Recognition Agreement (MRA)